Changes in serologic markers of hepatitis B in autologous hematopoietic stem cell transplantation recipients

Introduction: Hepatitis B virus (HBV) infection is one of the most prominent health threats worldwide. Hepatitis B exacerbation is a significant cause of morbidity and mortality in patients who are the candidates of cytotoxic, immunosuppressive therapy and hematopoietic stem cell transplantation (HSCT) in areas where chronic hepatitis B infection is endemic. Patient and Methods: This retrospective study was conducted in Bone Marrow Transplantation Unit. A total of 64 patients, who underwent autologous HSCT were retrospectively reviewed. Results: A total of 64 patients with median age of 57 (22–79) years and gender distribution of 66% (n = 42) males and 34% (n = 22) females, who underwent autologous HSCT were included in the study. Three patients who were identified as hepatitis B surface antigen (HBsAg) positive prior to the transplantation had autologous HSCT under lamivudine prophylaxis. HBV reactivation had occurred in one of these patients. Hepatitis B infection (reverse seroconversion) was identified in one of the two patients who were HBsAg negative and hepatitis B core antibody (anti-HBc) positive prior to the treatment via serologic tests performed due to transaminase increases observed on day 407 in one case and on day 222 in the other. Conclusion: HBsAg positivity constitutes an independent risk factor for HSCT. In addition, it is necessary to administer prophylaxis and/or be more cautious in HBsAg negative patients prior to the transplantation and those with antibody positivity as they are more likely to develop reverse seroconversion

A diffuse large B cell lymphoma emerging with breast cancer relapse

The prevalence of secondary cancers associated with the breast cancer treatment has increased, which is due to the administration of cytotoxic/hormonal drugs as well as radiotherapy. A 54-year-old female patient with a history of breast cancer for 4 years and receiving tamoxifen the hematology clinic with fatigue and nosebleed. Laboratory parameters were revealed pancytopenia. The bone marrow biopsy finding was compatible with CD20 positive high-grade B cell lymphoma resembling diffuse large B cell lymphoma. The patient started to receive a chemotherapy. Her hemogram values displayed an improvement after the second cycle. However, interim PET-BT, performed after the fourth cycle, showed an incomplete response in cervical lymphatic nodes. Then, a tru-cut biopsy was performed resulting in breast cancer metastasis. This is an unusual case of secondary-DLBCL presenting with pancytopenia and occuring 4 years after the diagnosis of breast cancer. In conclusion, clinicians should carefully set the dosage of chemotherapy drugs to avoid the long-term side effects associated with such drugs

Evaluation of neutrophil-lymphocyte ratio in patients with early-stage mycosis fungoides

Neutrophil-lymphocyte ratio (NLR), an indicator of inflammation, has been lately demonstrated as a prognostic factor and an indicator of disease activity in various diseases. However, the effects of NLR have not been investigated in mycosis fungoides (MF) patients yet. The aim of this study is to investigate the relationship between the NLR and treatment demand (systemic PUVA and/or chemotherapy), time to treatment, progression in stage, and time to progression in stage in MF patients. The data of 117 patients, who were followed with the diagnosis of MF at the Department of Dermatology in Istanbul Training and Research Hospital between April 2006 and January 2016, were analyzed retrospectively. The cutoff score for NLR was determined as 2 according to the median NLR level which was 1.96. At the time of diagnosis, the median age of patients was 54 years (range, 21-90) with 62 (53 %) female and 55 (47 %) male. Seventy-seven (65.8 %) patients required treatment during follow-up. Sixty-three (53.8 %) patients showed progression in disease stage. There was no significant difference in treatment demand, time to treatment, progression in stage, and time to progression in stage in patients with a NLR >= 2 and NLR< 2 (p = 0.331, 0.987, 0.065, and 0.119, respectively). It seems that there is no association between the NLR and treatment demand, time to treatment, progression in stage, and time to progression in stage in MF patients

Philadelphia-positive acute lymphoblastic leukemia in daily practice: A multicenter experience.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2013 -- Chicago, IL[No Abstract Available]Amer Soc Clin Onco

CLINICAL CHARACTERISTICS, POST-TREATMENT ASSESSMENT AND PROGNOSTIC FACTORS AFFECTING PATIENT SURVIVAL OF PATIENTS AT 65 YEARS OF AGE OR OLDER WITH HODGKIN LYMPHOMA: A RETROSPECTIVE MULTICENTER STUDY FROM TURKEY

Introduction: During the last three decades, major advances have been made in the therapy of Hodgkin's lymphoma. However, despite these advances, Hodgkin's lymphoma has a poor prognosis in the elderly. The proportion of Hodgkin's lymphoma patients aged > 60 ranges in the different reports between 15% and 35%. This study aimed to examine clinical characteristics, treatment outcomes and prognostic factors affecting patient survival in Hodgkin's lymphoma patients aged 65 years or older

COVID-19 in hematopoietic cell transplant recipients

In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients